{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:57:56Z","timestamp":1793977076754,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P01CA210944-01"],"award-info":[{"award-number":["1P01CA210944-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5-T32-HG-000046-16"],"award-info":[{"award-number":["5-T32-HG-000046-16"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31CA228455"],"award-info":[{"award-number":["F31CA228455"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["F31CA228455"],"award-info":[{"award-number":["F31CA228455"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["5-T32-HG-000046-16"],"award-info":[{"award-number":["5-T32-HG-000046-16"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["PD-1"],"award-info":[{"award-number":["PD-1"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["CTLA-4"],"award-info":[{"award-number":["CTLA-4"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0264"],"award-info":[{"award-number":["W81XWH-17-1-0264"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cell.2019.07.019","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:40:22Z","timestamp":1565260822000},"page":"933-948.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":518,"title":["Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade"],"prefix":"10.1016","volume":"178","author":[{"given":"Joseph L.","family":"Benci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexus R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Choa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. John","family":"Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy R.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Ishwaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy J.","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2019.07.019_bib1","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.066","article-title":"Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner","volume":"138","author":"Ahlenstiel","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2019.07.019_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib3","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2019.07.019_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"10.1016\/j.cell.2019.07.019_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygeno.2012.04.003","article-title":"Random forests for genomic data analysis","volume":"99","author":"Chen","year":"2012","journal-title":"Genomics"},{"key":"10.1016\/j.cell.2019.07.019_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1172\/JCI90745","article-title":"Blocking type I interferon signaling enhances T\u00a0cell recovery and reduces HIV-1 reservoirs","volume":"127","author":"Cheng","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2019.07.019_bib8","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1182\/blood-2008-10-187179","article-title":"Maturation of mouse NK cells is a 4-stage developmental program","volume":"113","author":"Chiossone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.07.019_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/ni.3809","article-title":"SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-\u03b2 signaling","volume":"18","author":"Cortez","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2019.07.019_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cell.2016.01.002","article-title":"Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells","volume":"164","author":"Dadi","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib11","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.cell.2019.07.019_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/1074-7613(94)90087-6","article-title":"Enhanced in\u00a0vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN \u03b3 receptors","volume":"1","author":"Dighe","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2019.07.019_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T\u00a0cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med."},{"key":"10.1016\/j.cell.2019.07.019_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ni.3800","article-title":"Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells","volume":"18","author":"Gao","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2019.07.019_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7554\/eLife.41090","article-title":"Rejection of immunogenic tumor clones is limited by clonal fraction","volume":"7","author":"Gejman","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.cell.2019.07.019_bib17","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2019.07.019_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41592-018-0033-z","article-title":"SAVER: gene expression recovery for single-cell RNA sequencing","volume":"15","author":"Huang","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cell.2019.07.019_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1198\/jasa.2009.tm08622","article-title":"High-Dimensional Variable Selection for Survival Data","volume":"105","author":"Ishwaran","year":"2010","journal-title":"J.\u00a0Am. Stat. Assoc."},{"key":"10.1016\/j.cell.2019.07.019_bib23","doi-asserted-by":"crossref","first-page":"E5528","DOI":"10.1073\/pnas.1522203113","article-title":"Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history\u00a0by next-generation sequencing","volume":"113","author":"Jiang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2019.07.019_bib24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T\u00a0cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2019.07.019_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8\u00a0T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In\u00a0vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib28","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T\u00a0cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T\u00a0cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2019.07.019_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cell.2019.07.019_bib32","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1073\/pnas.1220456110","article-title":"Interferon-\u03b3 mediates chemokine-dependent recruitment of natural killer cells during viral infection","volume":"110","author":"Pak-Wittel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2019.07.019_bib33","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T\u00a0cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2019.07.019_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cell.2019.07.019_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.07.019_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cell.2019.07.019_bib40","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T\u00a0cells ex\u00a0vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2019.07.019_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T\u00a0cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2019.07.019_bib42","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2019.07.019_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2019.07.019_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T\u00a0cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib45","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T\u00a0cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.cell.2019.07.019_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I Interferon in Chronic Virus Infection and Cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cell.2019.07.019_bib47","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.07.019_bib48","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ni.3482","article-title":"NK cells and type 1 innate lymphoid cells: partners in host defense","volume":"17","author":"Spits","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2019.07.019_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.cell.2019.07.019_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib52","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.07.019_bib54","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2019.07.019_bib55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.07.019_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.07.019_bib57","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867419307846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867419307846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:11:17Z","timestamp":1777475477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867419307846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0092867419307846"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2019.07.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736362848.793575385","asserted-by":"object"}]},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2019.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}